RACE-Seq identifies the Argonaute-2 cleavage products of RNA interference-based oligonucleotides
The recent announcement of the first successful Phase III clinical trial of a RNA interference (RNAi)-based therapeutic is a major achievement in the field. Synthetic RNAi therapeutic oligonucleotides are either first cleaved by Dicer or incorporate directly into the Argonaute-2 RNA-induced silencin...
| Main Author: | |
|---|---|
| Published: |
University of Westminster
2018
|
| Online Access: | https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.767183 |